Malignant Biliary Tract TumorsPhase 4NCT07790445
A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors
A Phase 4 study testing Oxaliplatin + 5-Fluorouracil/Leucovorin and Capecitabine in people with Malignant Biliary Tract Tumors, run by Zhai Wenlong at 1 site in China.
Trial summary
3. Study Design 3.1.1 Study Site and Overall Population Overview This study is a prospective, open-label, randomized controlled clinical trial designed to observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy compared with capecitabine in the adjuvant treatment of malignant biliary… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Biliary Tract Tumors
- What is being tested?
- Oxaliplatin + 5-Fluorouracil/Leucovorin and Capecitabine
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteChina
- Study dates
- 30 Jul 2026to 31 Dec 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years, male or female;
- Pathologically confirmed biliary malignancy (intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, gallbladder cancer, and distal cholangiocarcinoma), and had undergone curative surgery with negative surgical margins;
- No history of other tumors, and no antitumor therapy received before or after surgery (including but not limited to chemotherapy, immunotherapy, radiotherapy, targeted therapy, etc.);
- ECOG: 0-1;
- Baseline blood count tests and blood biochemistry must meet the following criteria: hemoglobin ≥80 g/L; absolute neutrophil count ≥1.5×10^9/L; platelet count ≥60×10^9/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN); total bilirubin ≤2 times ULN; serum creatinine ≤1.5 times ULN; albumin ≥30 g/L; INR <1.7 or PT prolongation not exceeding 4 seconds; serum creatinine less than 1.5 times the upper limit of normal;
- Women of childbearing potential must agree to use contraception during the study and for 6 months after the study ends (e.g., intrauterine device, contraceptive pills, or condoms); a serum or urine pregnancy test must be negative within 7 days before enrollment, and they must not be breastfeeding; male participants must agree to use contraception during the study and for 6 months after the study ends;
- Patients with active hepatitis B virus (HBV) infection must begin anti-HBV treatment during the screening phase and be willing to receive antiviral treatment throughout the study; patients who are hepatitis C virus (HCV) RNA positive must receive antiviral treatment according to standard treatment guidelines and have liver function elevations no higher than CTCAE grade 1.
- Subjects voluntarily join this study, sign the informed consent form, have good compliance, and are willing to cooperate with follow-up.
Who cannot join
- Pregnancy or lactation;
- Receipt of antitumor drug therapy for cholangiocarcinoma before or after surgery;
- Cardiac, pulmonary, or renal insufficiency, or severe hepatic insufficiency (Child-Pugh class C): severe cardiovascular and cerebrovascular disease (such as myocardial infarction within the past 6 months, unstable angina within the past 1 month, NYHA class III-IV heart failure, uncontrolled arrhythmia, or onset/worsening of congestive heart failure within the past 30 days). Severe respiratory disease (e.g., FEV1 1.8 mg/dL (or >160 μmol/L). Renal disease: chronic renal failure, MDRD ≥ stage III: GFR1.8 mg/dL (or >160 μmol/L) Uncontrolled active infection (e.g., severe suppurative cholangitis, sepsis), requiring intravenous antibiotics and hemodynamic instability. ⑤ ASA score >3; ⑥ BMI ≥35.;
- Active gastrointestinal bleeding, ulcer, or refractory ascites;
- Drug-uncontrolled hypertension, coagulation dysfunction, or severe portal hypertension;
- Tumor recurrence within 1 month after surgery;
Show all 11Show fewer
- History of other malignant tumors;
- Receipt of other clinical trial drugs within 28 days;
- Those deemed unsuitable for inclusion by the investigator.
- Allergy and contraindications: severe allergy to iodinated contrast media that cannot be relieved by premedication, or presence of contraindications to angiography.
- Postoperative pathology confirms non-biliary tract carcinoma.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052
Wenlong Zhai, MD, +86-371-66862231, ven0371@126.com
About this study
- Study Design 3.1.1 Study Site and Overall Population Overview This study is a prospective, open-label, randomized controlled clinical trial designed to observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy compared with capecitabine in the adjuvant treatment of malignant biliary tract tumors after radical surgery.
The study population consists of postoperative patients from the Hepatobiliary Surgery Department of our hospital, who are pathologically confirmed to have malignant biliary tract cancer (BTC), including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and other subtypes, and who have completed radical resection (R0 or R1 resection), with postoperative pathology confirming no distant metastasis. Using a computer-generated random sequence, participants will be assigned in a 1:1 ratio to either the hepatic arterial infusion chemotherapy group or the capecitabine group. The study will use recurrence-free survival (RFS) as the primary efficacy endpoint, and plans to enroll approximately 90 patients with malignant biliary tract tumors after radical surgery. After giving informed consent and being screened as eligible, participants will receive the following regimens:
Read more
Hepatic arterial infusion chemotherapy group:
Oxaliplatin 40 mg/m2 will be infused on days 1-3 of each cycle over 2 hours, followed by continuous infusion of 5-fluorouracil 800 mg/m2 over a total of 22 hours. One cycle lasts 4 weeks. Treatment will continue for 3-4 consecutive cycles or until disease progression, intolerable toxicity, or withdrawal for other reasons.
Capecitabine group:
Capecitabine, 1250 mg/m2, orally, twice daily (once in the morning and once in the evening, equivalent to a total daily dose of 2500 mg/m2), administered from day 1 to day 14 of each 3-week cycle (d1-14, q3w; that is, 2 weeks of continuous treatment followed by 1 week off). One treatment cycle lasts 3 weeks, and a total of 8 cycles will be administered.
- Conditions
- Malignant Biliary Tract Tumors
- Being tested
- Oxaliplatin + 5-Fluorouracil/Leucovorin, Capecitabine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oxaliplatin + 5-Fluorouracil/LeucovorinDrug
On days 1-3 of each cycle, oxaliplatin 40 mg/m2 will be infused for 2 h, followed by continuous infusion of 5-fluorouracil 800 mg/m2 for a total of 22 h. One cycle lasts 4 weeks. Treatment will continue for 3-4 cycles
CapecitabineDrug
Capecitabine, 1250 mg/m2, orally, twice daily (once in the morning and once in the evening, equivalent to a total daily dose of 2500 mg/m2), administered from day 1 to day 14 of each 3-week cycle (d1-14, q3w; i.e., 2 weeks on treatment followed by 1 week off). One treatment cycle lasts 3 weeks, for a total of 8 cycles
| Study group | Role | What they receive |
|---|---|---|
| Capecitabine | Active comparator | Participants will receive Capecitabine, 1250 mg/m2, orally, twice daily (once in the morning and once in the evening, equivalent to a total daily dose of 2500 mg/m2), administered on Days 1 to 14 of each 3-week cycle (d1-14, q3w; i.e., 2 weeks on treatment followed by 1 week off). The treatment cycle is 3 weeks. Treatment will be continued for a total of 8 cycles. Receives: Drug: Capecitabine |
| HAIC | Experimental | Participants will receive hepatic arterial infusion chemotherapy (HAIC) as follows: Oxaliplatin 40 mg/m2 will be infused over 2 hours on Days 1 to 3 of each cycle, followed by continuous infusion of 5-fluorouracil 800 mg/m2 for 22 hours. The treatment cycle is 4 weeks. Treatment will be continued for 3 to 4 cycles, or until disease progression, unacceptable toxicity, or withdrawal due to other reasons. Receives: Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival(PFS)
Measured: From date of randonization until disease progerssion or death, assessad up to 12 months
Recurrence-free survival (RFS)
Time from surgery to the first documented recurrence or death from any cause.
Measured: From the date of surgery until the date of first documented recurrence or death from any cause, whichever came first, assessed up to 12 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2026
- Study start30 Jul 2026
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Malignant Biliary Tract TumorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhai Wenlong
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Zhai Wenlong, The First Affiliated Hospital of Zhengzhou University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07790445
- Sponsor's protocol ID
- 2026-KY-0663-002
- Status last verified
- Sep 2026
- First submitted
- 7 Aug 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
[1] 中华医学会外科学分会胆道外科学组，中国医师协会外科医师分会胆道外科专家工作组. 胆道恶性肿瘤全程规范化管理中国专家共识（2023）[J]. 中华外科杂志,2024,62(6):504-513. [2] 中华医学会外科学分会胆道外科学组，中国医师协会外科医师分会胆道外科专家工作组. 胆道恶性肿瘤转化治疗专家共识（2025）[J]. 中华外科杂志,2025,63(6):453-460. [3] Wirasorn K, Ngamprasertchai T, Khuntikeo N, et al. Adjuvant chemotherapy in resectable cholangiocarcinoma patients[J]. Journal of Gastroenterology and Hepatology,2013,28. [4] Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis[J]. Surg Today,2017,47(2):182-192. [5] Primrose J N, Fox R P, Palmer D H, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. The Lancet. Oncology,2019,20(5):663-673. [6] Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet,2023,401(10372):195-203.
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors
- ClinicalTrials.gov ID
- NCT07790445
- Acronym / sponsor ID
- 2026-KY-0663-002
- Conditions
- Malignant Biliary Tract Tumors
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Zhai WenlongUniversity, hospital or other
- Study start
- 30 Jul 2026 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 27 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Study Design 3.1.1 Study Site and Overall Population Overview This study is a prospective, open-label, randomized controlled clinical trial designed to observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy compared with capecitabine in the adjuvant treatment of malignant biliary tract tumors after radical surgery.
The study population consists of postoperative patients from the Hepatobiliary Surgery Department of our hospital, who are pathologically confirmed to have malignant biliary tract cancer (BTC), including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and other subtypes, and who have completed radical resection (R0 or R1 resection), with postoperative pathology confirming no distant metastasis. Using a computer-generated random sequence, participants will be assigned in a 1:1 ratio to either the hepatic arterial infusion chemotherapy group or the capecitabine group. The study will use recurrence-free survival (RFS) as the primary efficacy endpoint, and plans to enroll approximately 90 patients with malignant biliary tract tumors after radical surgery. After giving informed consent and being screened as eligible, participants will receive the following regimens:
Hepatic arterial infusion chemotherapy group:
Oxaliplatin 40 mg/m2 will be infused on days 1-3 of each cycle over 2 hours, followed by continuous infusion of 5-fluorouracil 800 mg/m2 over a total of 22 hours. One cycle lasts 4 weeks. Treatment will continue for 3-4 consecutive cycles or until disease progression, intolerable toxicity, or withdrawal for other reasons.
Capecitabine group:
Capecitabine, 1250 mg/m2, orally, twice daily (once in the morning and once in the evening, equivalent to a total daily dose of 2500 mg/m2), administered from day 1 to day 14 of each 3-week cycle (d1-14, q3w; that is, 2 weeks of continuous treatment followed by 1 week off). One treatment cycle lasts 3 weeks, and a total of 8 cycles will be administered.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Capecitabine | Active comparator | Drug: CapecitabineParticipants will receive Capecitabine, 1250 mg/m2, orally, twice daily (once in the morning and once in the evening, equivalent to a total daily dose of 2500 mg/m2), administered on Days 1 to 14 of each 3-week cycle (d1-14, q3w; i.e., 2 weeks on treatment followed by 1 week off). The treatment cycle is 3 weeks. Treatment will be continued for a total of 8 cycles. |
| HAIC | Experimental | Drug: Oxaliplatin + 5-Fluorouracil/LeucovorinParticipants will receive hepatic arterial infusion chemotherapy (HAIC) as follows: Oxaliplatin 40 mg/m2 will be infused over 2 hours on Days 1 to 3 of each cycle, followed by continuous infusion of 5-fluorouracil 800 mg/m2 for 22 hours. The treatment cycle is 4 weeks. Treatment will be continued for 3 to 4 cycles, or until disease progression, unacceptable toxicity, or withdrawal due to other reasons. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age ≥18 years, male or female;
- Pathologically confirmed biliary malignancy (intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, gallbladder cancer, and distal cholangiocarcinoma), and had undergone curative surgery with negative surgical margins;
- No history of other tumors, and no antitumor therapy received before or after surgery (including but not limited to chemotherapy, immunotherapy, radiotherapy, targeted therapy, etc.);
- ECOG: 0-1;
- Baseline blood count tests and blood biochemistry must meet the following criteria: hemoglobin ≥80 g/L; absolute neutrophil count ≥1.5×10^9/L; platelet count ≥60×10^9/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN); total bilirubin ≤2 times ULN; serum creatinine ≤1.5 times ULN; albumin ≥30 g/L; INR <1.7 or PT prolongation not exceeding 4 seconds; serum creatinine less than 1.5 times the upper limit of normal;
Key exclusion criteria (11 listed)
- Pregnancy or lactation;
- Receipt of antitumor drug therapy for cholangiocarcinoma before or after surgery;
- Cardiac, pulmonary, or renal insufficiency, or severe hepatic insufficiency (Child-Pugh class C): severe cardiovascular and cerebrovascular disease (such as myocardial infarction within the past 6 months, unstable angina within the past 1 month, NYHA class III-IV heart failure, uncontrolled arrhythmia, or onset/worsening of congestive heart failure within the past 30 days). Severe respiratory disease (e.g., FEV1 1.8 mg/dL (or >160 μmol/L). Renal disease: chronic renal failure, MDRD ≥ stage III: GFR1.8 mg/dL (or >160 μmol/L) Uncontrolled active infection (e.g., severe suppurative cholangitis, sepsis), requiring intravenous antibiotics and hemodynamic instability. ⑤ ASA score >3; ⑥ BMI ≥35.;
- Active gastrointestinal bleeding, ulcer, or refractory ascites;
- Drug-uncontrolled hypertension, coagulation dysfunction, or severe portal hypertension;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oxaliplatin + 5-Fluorouracil/LeucovorinOn days 1-3 of each cycle, oxaliplatin 40 mg/m2 will be infused for 2 h, followed by continuous infusion of 5-fluorouracil 800 mg/m2 for a total of 22 h. One cycle lasts 4 weeks. Treatment will continue for 3-4 cycles | Drug | HAIC |
| CapecitabineCapecitabine, 1250 mg/m2, orally, twice daily (once in the morning and once in the evening, equivalent to a total daily dose of 2500 mg/m2), administered from day 1 to day 14 of each 3-week cycle (d1-14, q3w; i.e., 2 weeks on treatment followed by 1 week off). One treatment cycle lasts 3 weeks, for a total of 8 cycles | Drug | Capecitabine |
Primary outcome
Progression-Free Survival(PFS)
Time frame: From date of randonization until disease progerssion or death, assessad up to 12 months
Recurrence-free survival (RFS)
Time frame: From the date of surgery until the date of first documented recurrence or death from any cause, whichever came first, assessed up to 12 months.
Time from surgery to the first documented recurrence or death from any cause.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Results publication[1] 中华医学会外科学分会胆道外科学组，中国医师协会外科医师分会胆道外科专家工作组. 胆道恶性肿瘤全程规范化管理中国专家共识（2023）[J]. 中华外科杂志,2024,62(6):504-513. [2] 中华医学会外科学分会胆道外科学组，中国医师协会外科医师分会胆道外科专家工作组. 胆道恶性肿瘤转化治疗专家共识（2025）[J]. 中华外科杂志,2025,63(6):453-460. [3] Wirasorn K, Ngamprasertchai T, Khuntikeo N, et al. Adjuvant chemotherapy in resectable cholangiocarcinoma patients[J]. Journal of Gastroenterology and Hepatology,2013,28. [4] Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis[J]. Surg Today,2017,47(2):182-192. [5] Primrose J N, Fox R P, Palmer D H, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. The Lancet. Oncology,2019,20(5):663-673. [6] Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet,2023,401(10372):195-203.
- Individual participant dataSharing planned: Undecided
Related trials for Malignant Biliary Tract Tumors
RecruitingObservational study
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Thymoma, Stomach Neoplasms
RecruitingPhase 4
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Endometrial Cancer, Cervical Cancer
RecruitingPhase 1/2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Advanced Solid Tumor, Advanced Malignant Neoplasm
Recruiting
Distance-Based Exercise to Preserve Function and Prevent Disability
Localized Malignant Solid Neoplasm, Anal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Oxaliplatin + 5-Fluorouracil/Leucovorin and Capecitabine in people with Malignant Biliary Tract Tumors, run by Zhai Wenlong at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wenlong Zhai, MD (+86-371-66862231, ven0371@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival(PFS) (time frame: From date of randonization until disease progerssion or death, assessad up to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07790445, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.